1. Koumar L, Senthamizhselvan K, Barathi D, et al. Portal vein thrombosis in patients with cirrhosis of the liver: Prevalence and risk factors. Cureus 2023; 15: e50134.
2.
Pan J, Wang L, Gao F, et al. Epidemiology of portal vein thrombosis in liver cirrhosis: A systematic review and meta-analysis. Eur J Intern Med 2022; 104: 21-32.
3.
Zanetto A, Campello E, Senzolo M, Simioni, P. The evolving knowledge on primary hemostasis in patients with cirrhosis: A comprehensive review. Hepatology 2024; 79: 460-481.
4.
Galasso L, Cerrito L, Termite F, et al. The molecular mechanisms of portal vein thrombosis in hepatocellular carcinoma. Cancers 2024; 16: 3247.
5.
Turon F, Driever EG, Baiges A, et al. Predicting portal thrombosis in cirrhosis: a prospective study of clinical, ultrasonographic and hemostatic factors. J Hepatol 2021; 75: 1367-1376.
6.
Zhao F, Ding J, Cui J, et al. Platelet activation is upregulated in cirrhotic patients with portal vein thrombosis. Thromb Haemost 2024; 124: 739-752.
7.
Zanetto A, Rinder HM, Senzolo M, et al. Reduced clot stability by thromboelastography as a potential indicator of procedure-related bleeding in decompensated cirrhosis. Hepatol Commun 2020; 5: 272-282.
8.
Recommendations for the Standardization of Light Transmission Aggregometry: A consensus of the Working Party from the Platelet Physiology Subcommittee of SSC/ISTH. 2013.
9.
Lawrie AS, Mackie IJ, Machin SJ, Peyvandi F. Evaluation of an automated platelet-based assay of ristocetin cofactor activity. Haemophilia 2011; 17: 252-256.
10.
Lisman T, Caldwell SH, Intagliata NM. Haemostatic alterations and management of haemostasis in patients with cirrhosis.
11.
J Hepatol 2022; 76: 1291-1305.
12.
Zanetto A, Campello E, Burra P, et al. Increased platelet ratio in patients with decompensated cirrhosis indicates a higher risk of portal vein thrombosis. Liver Int 2023; 43: 155-159.
13.
Zanetto A, Campello E, Senzolo M, Simioni P. The evolving knowledge on primary hemostasis in patients with cirrhosis: A comprehensive review. Hepatology 2024; 79: 460-481.
14.
Campello E, Spiezia L, Gavasso S, et al. Endothelial damage of the portal vein is associated with heparin-like effect in advanced stages of cirrhosis. Thromb Haemost 2020; 120: 1173-1181.
15.
Zhao F, Ding J, Cui J, et al. Platelet activation is upregulated in cirrhotic patients with portal vein thrombosis. Thromb Haemost 2024; 124: 739-752.
16.
Quan X, Ye X, Qian S, et al. Portal vein thrombosis associates with high platelet-fibrin clot strength and platelet activation in decompensated cirrhosis: A retrospective study. Dig Liver Dis 2023; 55: 629-636.
17.
Altahan RM, Mathews N, Bourguignon A, et al. Evaluation of a diagnostic platelet aggregation test strategy for platelet rich plasma samples with low platelet counts. Int J Lab Hematol 2024; 46: 362-374.
18.
Curakova Ristovska E, Genadieva-Dimitrova M. Prognostic value of von-Willebrand factor in patients with liver cirrhosis and its relation to other prognostic indicators. World J Hepatol 2022; 14: 812-826.
19.
Lancellotti S, Basso M, Veca V, et al. Presence of portal vein thrombosis in liver cirrhosis is strongly associated with low levels of ADAMTS-13: a pilot study. Intern Emerg Med 2016; 11: 959-967.
20.
Sacco M, Tardugno M, Lancellotti S, et al. ADAMTS-13/von Willebrand factor ratio: a prognostic biomarker for portavein thrombosis in compensated cirrhosis. A prospective observational study. Dig Liver Dis 2022; 54: 1672-1680.
Copyright: © Clinical and Experimental Hepatology. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/) enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.